Effect of the drug LDS-751 on intrinsic tryptophan fluorescence of the P-glycoprotein multidrug transporter: a lifetime study

被引：0
|
作者：
Lugo, M [1 ]
Sharom, FJ [1 ]
机构：
[1] Univ Guelph, Guelph, ON N1G 2W1, Canada
来源：
BIOPHYSICAL JOURNAL | 2004年 / 86卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：556A / 556A
页数：1
相关论文
共 39 条
  • [31] In vitro assessment of the inhibitory effect of goreisan extract and its ingredients on the P-glycoprotein drug transporter and cytochrome P-450 metabolic enzymes
    Takiyama, Mikina
    Matsumoto, Takashi
    Kaifuchi, Noriko
    Mizuhara, Yasuharu
    Warabi, Eiji
    Ohbuchi, Katsuya
    Mizoguchi, Kazushige
    XENOBIOTICA, 2022, 52 (05) : 511 - 519
  • [32] Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts
    Lin, ZP
    Johnson, DR
    Finch, RA
    Belinsky, MG
    Kruh, GD
    Sartorelli, AC
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (12) : 1105 - 1114
  • [33] Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: Results of a long-term prospective study
    Dhooge, C
    De Moerloose, B
    Laureys, G
    Ferster, A
    De Bacquer, D
    Philippe, J
    Leroy, J
    Benoit, Y
    LEUKEMIA & LYMPHOMA, 2002, 43 (02) : 309 - 314
  • [34] The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: A positron emission tomography study
    Mairinger, Severin
    Bankstahl, Jens P.
    Kuntner, Claudia
    Roemermannd, Kerstin
    Bankstahl, Marion
    Wanek, Thomas
    Stanek, Johann
    Loescher, Wolfgang
    Muellner, Markus
    Erker, Thomas
    Langer, Oliver
    EPILEPSY RESEARCH, 2012, 100 (1-2) : 93 - 103
  • [35] Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line
    Perloff, MD
    von Moltke, LL
    Marchand, JE
    Greenblatt, DJ
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) : 1829 - 1837
  • [36] DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF STRONG CYP3A INHIBITION AND INDUCTION ON THE PHARMACOKINETICS OF AFICAMTEN, AND THE EFFECT OF AFICAMTEN ON P-GLYCOPROTEIN, IN HEALTHY PARTICIPANTS
    Xu, D.
    Lutz, J.
    Divanji, P.
    Cheplo, K.
    Li, J.
    Kupfer, S.
    German, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S85 - S85
  • [37] Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study
    Llaudo, Ines
    Colom, Helena
    Gimenez-Bonafe, Pepita
    Torras, Joan
    Caldes, Anna
    Sarrias, Maria
    Cruzado, Josep Ma
    Oppenheimer, Federico
    Sanchez-Plumed, Jaime
    Gentil, Miguel Angel
    Ekberg, Henrik
    Grinyo, Josep Ma
    Lloberas, Nuria
    TRANSPLANT INTERNATIONAL, 2013, 26 (02) : 177 - 186
  • [38] A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib
    Vikram Malhi
    Dawn Colburn
    Sarah J. Williams
    Cornelis E. C. A. Hop
    Mark J. Dresser
    Priya Chandra
    Richard A. Graham
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 41 - 49
  • [39] A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib
    Malhi, Vikram
    Colburn, Dawn
    Williams, Sarah J.
    Hop, Cornelis E. C. A.
    Dresser, Mark J.
    Chandra, Priya
    Graham, Richard A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (01) : 41 - 49
1234